Advanced searches left 3/3
Search only database of 8 mil and more summaries

Mmr Vaccine Coronavirus

Summarized by PlexPage
Last Updated: 02 July 2021

* If you want to update the article please login/register

General | Latest Info

Friday, Sept. 4 2020 - New clinical trial will try to determine whether measles, mumps and Rubella vaccines can protect health care workers from being infected with COVID - 19. Hundreds of millions of people have received the MMR vaccine since it was developed nearly 50 years ago. It's usually given to children before age 6. Growing evidence suggests that vaccines may also prevent COVID - 19. We know that the MMR vaccine is safe, and we think there are two main reasons that it could prevent COVID - 19, say researcher Dr. Michael Avidan, head of the Department of Anesthesiology at Washington University School of Medicine Louis. First is this vaccine includes small amounts of live but very weakened measles, mumps and Rubella viruses, Avidan explains in a University news release. This type of vaccine appears to strengthen the body's immune response to infections in general, not just to viruses in that particular vaccine. The MMR vaccine may also work because it protects against viruses that are similar to the Coronavirus. Researchers think that antibodies made To MMR vaccine might also fight SARS - CoV - 2. In addition, researchers hope that the MMR vaccine might make cases of COVID - 19 milder. The Trial is funded by a 9 million grant from the Bill and Melinda Gates Foundation, Wellcome Trust, Mastercard, and other public and philanthropic donors. Researchers hope to enroll as many as 30 000 health care workers around the world. Participants will be randomly selected to get the MMR vaccine or placebo. Most of those recruited for trial will receive booster, as they likely received vaccine as children. But in some countries where MMR vaccine isn't widely give, health care workers may be receiving vaccine for the first time, researchers note. Countries involved in study include Canada, Ghana, Ireland, South Africa, Uganda, United Kingdom, United States, Zambia and Zimbabwe. Each study participant will be followed for five months, and the entire trial is expected to last about a year, researchers say. Scientists at University College London will compile data from the trial.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Training the immune system

Clinical trials test drugs or medical devices on human beings. To get that far, vaccine has already shown promise in laboratory and in animal studies. Once the vaccine is ready for testing in human volunteers, US Food and Drug Administration requires success through three trial phases before approval for widespread use. The Phase 1 trial tests vaccine safety with tens of patients. Phase 2 trials test vaccine safety as well as its effectiveness at different doses with hundreds of patients. The Phase 3 trial tests vaccine safety and effectiveness with thousands of patients. The first vaccines being tested in the US will include 30 000 participants each, and trials will follow them for two years.


What is a vaccine?

Some of the first vaccines being tested in clinical trials introduce SARS - CoV - 2 spike proteins to the body in a fascinating way. Rather than injecting coronavirus spike proteins directly, vaccines deliver genetic instructions that make their way into shoulder - muscle cells near the injection site. One vaccine now being tested introduces genetic instructions to muscle cells in a tiny fatty envelope; another vaccine does so using weakened common - cold virus called adenovirus. Once in muscle cells, mRNA instructs those cells to produce coronavirus spike proteins that then trigger immune response. Other vaccine types used to spur immune response include DNA vaccines that introduce DNA to induce human cells to churn out virus proteins; inactivate and live attenuate vaccines that use inactive or weakened forms of target virus; and vaccines that directly introduce viral proteins or protein fragments.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

The evidence behind the theory

Six major types of candidate vaccine for coronavirus disease 2019 are illustrate, showing the number of candidate vaccines that are currently under clinical and preclinical development. Nucleic acid - base platforms include both mRNA Vaccines and plasmid DNA Vaccines. Data obtained from ref. 5. In response to urgent demand for vaccine, more than two dozen candidate vaccines are advancing through clinical trials following an expedited pandemic vaccine development paradigm, with many steps of development process occurring in parallel before successful outcome of previous steps has been confirm. Vaccine candidates will continue to be preclinically and clinically evaluated following a conventional and / or rationalized vaccine development process over the next few years. These efforts will evolve to meet demands for vaccination in several likely scenarios that are predicted on basis of sociopolitical challenges and emerging data regarding trajectory of coronavirus disease 2019 pandemic and host response to severe acute respiratory syndrome coronavirus 2. One scenario is priority vaccination of high - risk populations such as health - care workers, seniors, people with co - morbidities and ethnic minorities, WHO has been disproportionately affected by COVID - 19, when vaccine supply is initially limited. Aside from these prioritize groups, it may also be necessary to consider that asymptomatic individuals, patients WHO have recovered from COVID - 19 but generate poor immunity or whose immunity quickly wan, and individuals WHO receive rapidly developed pandemic vaccine that provide suboptimal protection or rapidly waning immune responses may require booster vaccination to ensure sufficient levels of population protection for herd immunity. Ultimately, regional, continental and global populations will be subject to mass vaccination programmes based on the extent of national and global vaccine distribution and also likely according to relative regional severity of outbreaks.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Progressing to clinical trial

Table

DEVELOPER(S)VACCINE METHODEVIDENCESTATUS
Multiple organizations InternationalThe Bacille Calmette-Guerin (BCG) vaccine for tuberculosis consists of live attenuated Mycobacterium bovis .Lower rates of COVID-19-related deaths in countries with mandatory BCG vaccination prompted the launch of several clinical trials to test whether the immune response triggered by the vaccine may protect against SARS-CoV-2.Several Phase 3 and 4 trials are underway .
Multiple organizations InternationalThe measles-mumps-rubella (MMR) vaccine consists of live-attenuated strains of the three viruses.Epidemiological data have revealed that places where the MMR vaccine is given as standard medical care have lower COVID-19 death rates than areas where MMR vaccination is not standard. Additionally, sailors aboard the U . S . S . Roosevelt who tested positive for COVID-19 had mostly mild symptoms, which some researchers suspect may have been due to administration of the MMR vaccine to all US Navy recruits.A Phase 3 trial is underway in Egypt, led by researchers at Kasr El Aini Hospital. Separately, researchers at the Washington University School of Medicine are running an international Phase 3 trial of healthcare workers in the US, Canada, Europe, and Africa.
Immunovative Therapies, Mirror Biologics USAn off-the-shelf living immune cellThe affiliated companies are currently testing the formulation as a therapeutic vaccine for chemotherapy-refractory metastatic cancers .A Phase 1/2 trial for healthy older adults has been approved to begin in New York.
Canadian Cancer Trials Group, others Can adaHeat-killed Mycobacterium obuenseThe vaccine is intended to stimulate nonspecific innate immunity. The company is also testing the vaccine in clinical trials for cancer .A Phase 3 trial has been approved to begin in Canada .
Bandim Health Project Guinea-BissauOral polio vaccine, an attenuated strain of the poliovirusResearchers argue that the vaccine is safer and available in greater quantities than the BCG vaccine against tuberculosis, which is also being tested as a possible COVID-19 preventive.A Phase 4 trial has been approved to begin in Guinea-Bissau in West Africa.
Inmunotek, BioClever Mexi coA mixture of inactivated bacteriaThe vaccine is intended to stimulate nonspecific innate immunity.A Phase 3 trial for healthcare workers has been approved to begin in Mexico.
Pulmotect USAn inhaled combination of two synthetic Toll-like receptor agonistsThe vaccine was originally developed as a potential therapeutic for cancer and has undergone early stage clinical testing. In mice, it provided protection against a range of respiratory pathogens, including MERS and SARS.A Phase 2 trial for people with known SARS-CoV-2 exposure is underway in several US states.

Adults who receive MMR Vaccine as children will likely still have antibodies against measles, mumps and rubella viruses, but are unlikely to still have MDSCs, say Dr. Fidel. This means they would require booster vaccination to obtain potential benefits against COVID - 19. While MDSCs are long - live, they are not life - long cells. So, booster MMR would enhance antibodies to measles, mumps, and rubella and reinitiate MDSCs. We would hope that MDSCs induced by MMR would have a fairly good life - span to get through the critical time of pandemic. Researchers have proposed a clinical trial of MMR Vaccine in high - risk healthcare workers and first responders in New Orleans. They have also been awarded a grant to compare MMR and BCG Vaccines in primate model of COVID - 19. If their hypothesis is correct, authors say USE of MMR Vaccine could present a low - risk - high - reward measure to save lives during the COVID - 19 pandemic.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Sources

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summaries are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo

© All rights reserved
2021 made by Algoritmi Vision Inc.

If you believe that any of the summaries on our website lead to misinformation, don't hesitate to contact us. We will immediately review it and remove the summaries if necessary.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.